Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.
Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.
Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.
Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.
Evotec has entered into a research collaboration with Immuneering on artificial intelligence (AI) driven ligand identification for rare hereditary metabolic diseases.
LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).
Boehringer Ingelheim has entered into a new global collaboration with Epizyme to develop novel epigenetic oncology therapies.
NextCure, a biopharmaceutical firm engaged in the discovery and development of next generation immunomedicines for cancer and other diseases, has raised $93m in Series B financing.
Gene editing company CRISPR Therapeutics and cell-based medicines and life sciences firm MaxCyte have expanded clinical and commercial license agreement into oncology.
Nestlé Health Science has increased its stake in biopharmaceutical firm Aimmune Therapeutics by making an additional equity investment of $98m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.